Sinovac Biotech Ltd. develops, manufactures and commercializes vaccines and related biological products for human infectious diseases. The China-based biopharmaceutical company’s marketed portfolio includes vaccines for influenza, viral hepatitis, varicella, hand-foot-mouth disease associated with EV71, poliomyelitis, pneumococcal disease and COVID-19, and its pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Company updates commonly address vaccine sales, research and development progress, product approvals, overseas market activity and financial reporting. Recent corporate developments also include Nasdaq listing-compliance matters, auditor engagement, SEC filing status and governance proceedings involving board composition and shareholder-meeting disputes.
Sinovac (NASDAQ: SVA) reported unaudited results for the six months ended June 30, 2026. Sales rose 12.9% year over year to $147.1 million, driven by an 82.3% increase in overseas revenue to $66.5 million, which represented 45.2% of total sales.
Gross profit increased to $95.5 million and gross margin improved to 65.0%, supported by higher-margin international sales and cost efficiencies. Despite lower SG&A and R&D expenses, the company recorded a net loss of $91.4 million and a net loss attributable to common shareholders of $60.2 million, or $0.84 per share.
Cash and restricted cash totaled $998.5 million. Sinovac advanced its pipeline with NMPA approval of its PVRV-SF rabies vaccine, priority review for its HFMD2 vaccine NDA, and five additional late‑stage candidates, while planning a PCV13 NDA submission in the third quarter of 2026.
SINOVAC (NASDAQ: SVA) announced an extension of the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share, payable to valid holders of common shares as of May 23, 2025 (ET).
The submission deadline, first set for December 31, 2025 and then June 30, 2026, is now extended to December 31, 2026. Holders who have not submitted instruction materials are reminded to do so by that date, and may contact information agent D.F. King for assistance.
Sinovac (Nasdaq: SVA) announced it has regained compliance with Nasdaq Global Market listing requirements. A June 10, 2026 Nasdaq notification confirms compliance with Listing Rule 5250(c)(1).
The company filed its 2025 Form 20-F on June 5, 2026 and remains under Mandatory Panel Monitor until May 20, 2027.
SINOVAC (NASDAQ:SVA) filed its 2025 Form 20-F and reported unaudited second-half and audited full-year 2025 results.
2025 sales were $386.0M vs $361.4M in 2024, with overseas sales up 93.9% to $124.8M. Net loss attributable to common shareholders was $59.7M vs $90.9M income in 2024, impacted by $202.8M impairments and lower investment income.
Sinovac (Nasdaq:SVA) announced it received a Nasdaq delist determination on May 22, 2026, due to not timely filing its 2025 Form 20-F annual report. The company has requested a hearing, triggering an automatic 22-day stay on any suspension, and also requested a further stay.
Sinovac had previously regained compliance on May 8, 2026, after filing its 2024 Form 20-F and 2025 Q2 Form 6-K, and is under a one-year Nasdaq panel monitoring period.
Sinovac (NASDAQ:SVA) extended the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share. Eligible holders of common shares as of May 23, 2025 now have until June 30, 2026 to submit required materials.
Sinovac (NASDAQ: SVA) reported unaudited H1 2025 results: sales $130.3M, gross profit $81.5M (margin 62.5%), and net loss attributable to common shareholders $21.7M or $0.30 per share. Cash and restricted cash totaled $4.2B. Overseas sales rose 29.4%. The company recorded a $68.1M impairment on IPR&D and goodwill and declared a special cash dividend of $55.00 per share.
Key R&D milestones include marketing approval for an adsorbed tetanus vaccine and multiple programs entering Phase III or Phase I trials. Prior-period financials were restated and should no longer be relied upon.
Sinovac (Nasdaq: SVA) filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 30, 2026. An electronic copy is available on the company's investor relations website and on the SEC website.
Sinovac (Nasdaq: SVA) said the Nasdaq Hearings Panel granted its request to continue listing, conditional on remediation of filing delinquencies and completion of its financial audit.
The company must demonstrate compliance by May 11, 2026 by filing its Form 20-F for year ended Dec 31, 2024 and an interim Form 6-K containing an end-of-second-quarter 2025 balance sheet and income statement. Sinovac disclosed it engaged Zhonghua Certified Public Accountants LLP as its independent registered public accounting firm (disclosed Jan 4, 2026) and is working with Zhonghua to complete the required audit and regain compliance.
Sinovac (NASDAQ: SVA) said the Antigua High Court updated an interlocutory order naming ten directors to comprise the Company board until the trial listed in late April/early May 2026, and noted that Rui-Ping Xiao resigned for personal reasons. The Company also announced the Audit Committee approved engagement of Zhonghua as independent auditor effective December 31, 2025. Zhonghua is registered in China and with the PCAOB, and its engagement supersedes UHY LLP.
The company said seven of nine board members are independent and all Audit, Compensation and Nominating & Corporate Governance committee members are independent.